Determining Immunogenicity for CAR-T cell Therapies
Chimeric Antigen Receptor (CAR)-T cell therapy is a novel cancer therapy that harnesses and redirects the cytotoxic activity of T cells against cancer cells. CAR-T cells are generated by engineering T cells to express a chimeric antigen receptor, which is typically an antibody directed against a target on the cancer cell, fused with TCR signaling components. Several CAR-T cell products have been approved for treatment of hematological cancers, and there are numerous ongoing trials with CAR-T therapies across a broad spectrum of disease indications. Given the broad investment in this new and potentially powerful therapy, it is important to have the appropriate analytical strategies in place to accurately measure the safety and efficacy of these novel modalities.